Table 2. Presenting characteristics of... | American Society of Hematology

Table 2.

Presenting characteristics of patients who had primary refractoriness to imatinib and/or chemotherapy

No.	Age, y/sex	Hb level, g/dL	WBC count, × 10⁹/L	Platelet count, × 10⁹/L	LDH level, IU/L	EMI	Immunophenotype	Karyotype	BCR-ABL isoform
10^*	27/M	11.6	223.6	22.0	6366	No	B-lineage	46,XY,del(9)(p22),t(9;22)(q34;q11.2),der(19) t(9;19)(q12;q13)[14]/48,idem, + 8, - der (19)t(9;19), + der(22)t(9;22)[10]/46,XY[1]	p190
12†	39/M	8.0	179.2	15.0	1880	Yes	B-lineage	46,XY,t(9;22)(q34;q11.2)[16]/46,XY[4]	p210
14‡	44/M	12.0	122.7	58.0	2050	No	B + My	45,XY, - 7,t(9;22)(q34;q11.2)[25]	p190
16†	31/M	10.2	4.7	23.0	1159	Yes	B + My	46,XY,t(9;22)(q34;q11.2)[20]	p190
19†	28/F	7.9	13.4	12.0	4470	No	B + My	46,XX,t(9;22)(q34;q11.2),del(9)(p22)[3]/47, idem, + der(22)t(9;22)[17]	p190
24‡	44/F	10.2	1.8	33.0	574	Yes	B-lineage	46,XX,t(9;22)(q34;q11.2)[25]	p190
26‡	20/M	10.5	102.5	32.0	1082	Yes	B + My	45,XY, - 7,t(9;22)(q34;q11.2)[12]/45,idem, der(16)t(1;16)(q12;q11.2)[2]/46,XY[11]	p190

No.	Age, y/sex	Hb level, g/dL	WBC count, × 10⁹/L	Platelet count, × 10⁹/L	LDH level, IU/L	EMI	Immunophenotype	Karyotype	BCR-ABL isoform
10^*	27/M	11.6	223.6	22.0	6366	No	B-lineage	46,XY,del(9)(p22),t(9;22)(q34;q11.2),der(19) t(9;19)(q12;q13)[14]/48,idem, + 8, - der (19)t(9;19), + der(22)t(9;22)[10]/46,XY[1]	p190
12†	39/M	8.0	179.2	15.0	1880	Yes	B-lineage	46,XY,t(9;22)(q34;q11.2)[16]/46,XY[4]	p210
14‡	44/M	12.0	122.7	58.0	2050	No	B + My	45,XY, - 7,t(9;22)(q34;q11.2)[25]	p190
16†	31/M	10.2	4.7	23.0	1159	Yes	B + My	46,XY,t(9;22)(q34;q11.2)[20]	p190
19†	28/F	7.9	13.4	12.0	4470	No	B + My	46,XX,t(9;22)(q34;q11.2),del(9)(p22)[3]/47, idem, + der(22)t(9;22)[17]	p190
24‡	44/F	10.2	1.8	33.0	574	Yes	B-lineage	46,XX,t(9;22)(q34;q11.2)[25]	p190
26‡	20/M	10.5	102.5	32.0	1082	Yes	B + My	45,XY, - 7,t(9;22)(q34;q11.2)[12]/45,idem, der(16)t(1;16)(q12;q11.2)[2]/46,XY[11]	p190

M indicates male; F, female; Hb, hemoglobin; EMI, extramedullary involvement; My, myeloid antigen.

Patient with refractoriness to imatinib therapy

Patients with refractoriness to chemotherapy

Patients with refractoriness to both imatinib therapy and chemotherapy